A single, unified set of magnetic resonance imaging (MRI) criteria that can apply to relapsing remitting multiple sclerosis (MS) and primary progressive MS should be considered for future revisions to the McDonald diagnostic criteria,...
A single, unified set of magnetic resonance imaging (MRI) criteria that can apply to relapsing remitting multiple sclerosis (MS) and primary progressive MS should be considered for future revisions to the McDonald diagnostic criteria,...
Levosimendan was not better than placebo at maintaining respiratory function for patients with amyotrophic lateral sclerosis, according to a recent study published in The Lancet Neurology.
Levosimendan was not better than placebo at maintaining respiratory function for patients with amyotrophic lateral sclerosis, according to a recent study published in The Lancet Neurology.
Evidence for superiority of migraine specific preventive therapies over non-specific traditional oral prophylaxis includes all of the following except:Placebo-subtracted analyses of efficacy, safety, and tolerability data all favor new...
Evidence for superiority of migraine specific preventive therapies over non-specific traditional oral prophylaxis includes all of the following except:Placebo-subtracted analyses of efficacy, safety, and tolerability data all favor new...
Increased REM sleep without atonia variable subscores are present in prediagnostic Parkinson disease, independent of REM sleep behavior disorder status, according to findings presented at MDS Virtual Congress 2021.
Increased REM sleep without atonia variable subscores are present in prediagnostic Parkinson disease, independent of REM sleep behavior disorder status, according to findings presented at MDS Virtual Congress 2021.
Patients with multiple sclerosis (MS) treated with ocrelizumab can develop vaccine-specific T-cell responses to the SARS-CoV-2 messenger RNA vaccine, despite ocrelizumab being a B-cell-depleting agent, according to new research published in...
Patients with multiple sclerosis (MS) treated with ocrelizumab can develop vaccine-specific T-cell responses to the SARS-CoV-2 messenger RNA vaccine, despite ocrelizumab being a B-cell-depleting agent, according to new research published in...
Alzheimer disease (AD) co-pathology is associated with presence and severity of neuropsychiatric symptoms in Lewy body dementia, according to recent findings presented at MDS Virtual Congress 2021.
Alzheimer disease (AD) co-pathology is associated with presence and severity of neuropsychiatric symptoms in Lewy body dementia, according to recent findings presented at MDS Virtual Congress 2021.
Symptoms including pain, fatigue, depression, and anxiety occur in newly diagnosed multiple sclerosis, according to new research observing the presence and trajectories of these symptoms.
Symptoms including pain, fatigue, depression, and anxiety occur in newly diagnosed multiple sclerosis, according to new research observing the presence and trajectories of these symptoms.
Prevention for migraine should be?Considered for patients with 6 or more monthly headache days and no disabilityOffered to patients with 3 or more monthly headache days with some disabilityOffered to patients with 4 or more monthly...
Prevention for migraine should be?Considered for patients with 6 or more monthly headache days and no disabilityOffered to patients with 3 or more monthly headache days with some disabilityOffered to patients with 4 or more monthly...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke.
“In aging...
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke.
“In aging...
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
To view accreditation information/faculty disclosures for the program, click
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
To view accreditation information/faculty disclosures for the program, click
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
To view accreditation information/faculty disclosures for the program, click
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
To view accreditation information/faculty disclosures for the program, click